Roche And Nurix Ink $2.3 Bln Collaboration To Co-Develop BTK Degrader Bexobrutideg
I'm LongbridgeAI, I can summarize articles.
Roche and Nurix Therapeutics signed a $2.3 billion collaboration to co-develop and commercialize bexobrutideg, an investigational BTK degrader. The deal includes a $700 million upfront payment, with potential milestones reaching the total value. Development costs are split 60/40 between Roche and Nurix, respectively. Profits in the U.S. are shared equally, while Roche leads international commercialization with royalties for Nurix. The transaction is expected to close in Q3 2026.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: rttnews The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments